ABATTIS on BTV JULY 20, 2014

ABATTIS on BTV JULY 20, 2014

Vancouver, BC – June 18, 2014 - Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (OTC PINK: ATTBF) (CSE: ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, today announced they will be part of a BTV segment airing July 20, 2014.

http://www.b-tv.com/the-btv-show/episodes.html?id=230

Medical Marijuana on BTV Headlining Abbatis, Lexaria, Endexx, & Affinor Growers

Business Television goes on location to bring investors expert analyst commentary and stories on emerging companies for their portfolio.

Commentary from:

·       Alan Brochstein - Analyst, 420Investor on what to check in cannabis companies: video

·       Cannabis trends: video

·       Technology in marijuana space: video

·       Marijuana stocks: video

·       Horst Hueniken - President, Dundee Agricultural Corp. on medical marijuana sector: video

·       Technology in cannabis space: video

BTV, a half-hour weekly business news program, profiles emerging companies across Canada and the USA to bring investors information for their portfolio. With Host Taylor Thoen, BTV features companies at their location, interviews the company's key executives and features their business.

BTV BROADCAST TIMES:

·       CANADA: BNN - Sunday, July 20 @ 9:30am & 8:00pm EST

·       Bell Express Vu - Sunday, Jun 20 @ 9:30am & 8:00pm EST

·       U.S. National: Fox Business News - Sunday, July 20 @ 5:00pm EST

·       America One - Saturday, July 19 @ 10am EST

·       Biz Television Network - Thurs. Jul 24 @ 10:00pm & 1:00am EST and Sun Jul 27 @ 12:30pm, 9:00pm & 12:00am EST

About Abattis Bioceuticals Corp.

Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The Company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions, by supplying and partnering with companies to employ its mass cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: www.abattis.com.

ON BEHALF OF THE BOARD

"Mike Withrow"

Michael Withrow, President & CEO

For further information, contact the Company's CEO, Michael Withrow at (778) 896-6536 or at news@abattis.com.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY ORACCURACY OF THIS RELEASE.

FORWARD LOOKING INFORMATION

This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.